Filing summary
Entity and period: The supplied filing is Immudyne, Inc.’s Form 10-K for the fiscal year ended December 31, 2014, filed March 30, 2015. It is not identified as a LifeMD, Inc. filing. Results below are annual, not fourth-quarter-only.
Business context
Immudyne manufactured and sold yeast beta-glucan ingredients and branded nutraceutical and cosmetic products. Sales were primarily business-to-business, with plans to expand distribution, healthcare-professional marketing, and direct-to-consumer sales. The company reported three full-time and 13 part-time employees at year-end.
Financial performance and liquidity
| Metric | FY 2014 | FY 2013 |
|---|---|---|
| Sales | $714,158 | $808,363 |
| Gross profit / margin | $541,308 / 76% | $627,059 / 77% |
| Operating expenses | $1,072,187 | $1,173,467 |
| Operating loss | $(530,879) | $(546,408) |
| Net loss | $(460,485) | $(268,262) |
| Basic and diluted loss per share | $(0.02) | $(0.01) |
| Cash from operating activities | $33,439 | $(259,074) |
| Cash from financing activities | $(113,000) | $315,200 |
| Cash at year-end | $75,495 | $155,056 |
At December 31, 2014, current assets were $131,473 and current liabilities were $301,519, producing negative working capital of approximately $170,000 and a 0.4-to-1 current ratio. Total liabilities were $314,719; stockholders’ equity was a deficit of $139,498. Notes payable were $27,200, due to officers, directors, and related individuals and payable on demand with interest at 5%. Accounts payable and accrued expenses were $274,319, including approximately $133,000 related to a royalty obligation.
The reported positive operating cash flow in 2014 should be viewed in context: management attributed the improvement primarily to receipt of $132,000 in legal-settlement proceeds, alongside working-capital movements. The auditor stated that accumulated losses and negative cash flows raised substantial doubt about the company’s ability to continue as a going concern.
Changes, outlook, and notable risks
- Sales declined 12% in 2014, which management attributed mainly to failure to execute plans to generate new business. The chief marketing officer resigned during the year; three senior marketing executives were hired late in 2014 and early in 2015.
- Net loss increased by approximately $192,000. A key comparison factor was 2013’s $210,000 of net legal-settlement proceeds; 2014 also had lower sales and continued operating costs. Operating expenses fell 9%, but this did not offset lower gross profit and reduced other income.
- Management said existing resources were insufficient for the next 12 months and expected operations, together with a first-quarter 2015 short-term loan, to fund the business through the first half of 2015. The company obtained a $100,000 On Deck Capital loan in January 2015, requiring 252 daily principal-and-interest payments of $492. Further financing or increased sales would be needed; no assurance was given that financing would be available.
- Customer concentration was acute: the largest customer represented 79% of 2014 sales and 100% of year-end receivables; the second-largest represented 12% of sales. Management anticipated concentration would persist in the near term.
- The company reported material weaknesses in internal controls and ineffective disclosure controls, citing inadequate segregation of duties, insufficient written accounting and reporting procedures, ineffective period-end reporting controls, and limited board oversight. Remediation depended on available funding.
- Products are dietary supplements and cosmetics, not approved treatments. The filing states that cited research was not overseen by the FDA or another comparable regulator, and the company cannot make disease-treatment or prevention claims. The company also disclosed that it did not maintain product-liability insurance.
- Other notable exposures include dependence on its Kentucky manufacturing facility, limited and illiquid OTC trading, potential shareholder dilution, and related-party arrangements. A royalty agreement requires 8% of sales of certain skincare products up to a stated cap; the president has a 60% interest in the royalty payments and had deferred payments.
- No specific revenue or earnings guidance was provided. Management’s stated strategy was to expand marketing and distribution, including internationally, while acknowledging that execution, capital availability, regulatory restrictions, and customer concentration could impede growth.
Most important facts to verify
- Confirm the issuer identity: the filing names Immudyne, Inc., whereas the request metadata names LifeMD, Inc.
- Review the audited financial statements and going-concern disclosure, including the negative working capital, cash balance, and subsequent $100,000 loan’s repayment terms.
- Assess whether 2014 operating cash flow is repeatable given the settlement receipt and working-capital changes.
- Verify customer-contract status, concentration, receivable collectability, and the company’s ability to diversify sales.
- Review the royalty accrual and related-party terms, as well as the reported material control weaknesses and remediation progress.
- Check the complete filing for any details not present in the supplied text; this summary is based on the provided filing excerpt.